JP2003160497A - Skin care preparation - Google Patents

Skin care preparation

Info

Publication number
JP2003160497A
JP2003160497A JP2001398249A JP2001398249A JP2003160497A JP 2003160497 A JP2003160497 A JP 2003160497A JP 2001398249 A JP2001398249 A JP 2001398249A JP 2001398249 A JP2001398249 A JP 2001398249A JP 2003160497 A JP2003160497 A JP 2003160497A
Authority
JP
Japan
Prior art keywords
skin
ginsenoside
ginseng
skin care
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001398249A
Other languages
Japanese (ja)
Inventor
Tatsuhiko Tsutsumi
龍彦 堤
Eiji Fujita
英治 藤田
Seishi Matsubara
征志 松原
Fumihiko Miura
文彦 三浦
Sangu Soo Jungu
サング ソー ジュング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TOSHIN KAGAKU KK
Original Assignee
TOSHIN KAGAKU KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TOSHIN KAGAKU KK filed Critical TOSHIN KAGAKU KK
Priority to JP2001398249A priority Critical patent/JP2003160497A/en
Publication of JP2003160497A publication Critical patent/JP2003160497A/en
Pending legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To solve the problem that a ginseng and Panax ginseng are utilized as a crude medicine from old times, and formulated with the skin care preparation such as a cosmetic, but a skin care preparation being more effective or having stronger effectiveness is desired. <P>SOLUTION: This skin care preparation contains ginsenoside Rh<SB>2</SB>and/or ginsenoside Rg<SB>3</SB>formulated therewith. <P>COPYRIGHT: (C)2003,JPO

Description

【発明の詳細な説明】 【0001】 【発明の属する技術分野】本発明は医薬品、医薬部外品
や化粧品などの細胞賦活作用あり、特に皮膚免疫調整作
用のある皮膚外用剤に関するものである。さらに詳しく
は酵素処理法により生産されたジンセノサイドRh
よび/またはジンセノサイドRgの抽出物を含む安全
で有効な皮膚外用剤に関するものである。 【0002】 【従来の技術】高麗人参、オタネ人参など(以下薬用人
参と略する)は古くより、生薬として利用されており、
化粧品等の皮膚外用剤にも配合されている。(特開昭5
0−95416号、特開昭55−127317号、特開
昭58−113116号、特開昭59−55809号の
各公報)また、育毛剤としても広く利用されている。
(特開昭60−38314号、特開昭60−19981
0、特開昭60−222409号、特開昭60−255
715号の各公報)化粧品への利用は主として、細胞を
活性化する働きに注目し添加されている。また、最近の
研究で、薬用人参に免疫調整作用があり、癌に有用であ
ることもわかってきた。その中で、特に野生の薬用人参
に多く含まれるジンセノサイドRh、ジンセノサイド
Rgがその効果が強いことも最近の研究成果の1つと
して判明してきた。 【0003】 【発明が解決しようとする課題】化粧品をはじめとする
皮膚外用剤は長期間に渡って連用されることがあり、皮
膚という面積の多い臓器に適用されるため、安全性は最
重視される項目の1つでまた、皮膚外用剤にとって必要
な有効性は様々にあり、皮膚の老化防止、肌荒れ防止な
どの効果が求められている。また、日本人など有色人種
は肌が白いことは美しさに繋がり美白は皮膚外用剤に求
められる効果として大きい。さらに皮膚の持つ機能は乾
燥した大気中でも生活出来るように体内からの水分を失
わないように保つことや外的な物理的な防御的な機能は
勿論あるが、最近の研究によって、皮膚は免疫に関して
も重要な役割を果たしていることがわかりつつある。皮
膚は、表皮の角化細胞、ランゲルハンス細胞、真皮の樹
状細胞、血管内皮細胞、マクロファージ等から構成され
ているが、外部からの異物としての抗原の侵入に対し、
すみやかに接触して処理し、リンパ節へ移動してT細胞
にそれを提示し、以後の一連の免疫応答反応が始まると
考えられている。そして、紫外線を浴びることやストレ
スによってこの免疫機能が低下することもわかってお
り、発ガンに至らなくとも種々の皮膚疾患(疾患に至ら
ないものも含めて皮膚の異常)を発生させるおそれがあ
り皮膚免疫の正常化は充分考慮されるべき項目である。
そして、皮膚での免疫の働きは他の臓器とは大きく異な
り、他の免疫に関係することが、わかっていても、皮膚
での働きはまた異なることが多い。 【0004】 【発明が解決するための手段】安全性と皮膚への有効性
を考え、鋭意検討した結果、人参などの植物に含まれる
有用成分であるジンセノサイドRhおよび/またはジ
ンセノサイドRgを用いた皮膚外用剤が本発明の目的
に最適なことか判明した。本発明では、酵素処理法を用
いて生産されたジンセノサイドRhおよび/またはジ
ンセノサイドRgを配合する事により皮膚免疫正常化
効果が強く、さらに細胞賦活効果など皮膚に有用な皮膚
外用剤を本発明者が検討、開発した。 【0005】ジンセノサイドRhおよび/またはジン
セノサイドRgはジンセノサイド類を含有する植物の
全体又は一部分をそのまま用いて、或いは加工処理(例
えば、乾燥、切断、湯通し、蒸気加熱、若しくは粉末
化)したものより抽出することが可能である。しかし、
当然薬用人参にその含有量が高いので、これより抽出す
ることが多い。その種類を例示すれば、ウコギ科のオタ
ネニンジン(Panaxginseng C.A.Me
yer;Panax schinseng Nee
s)、トチバニンジン(Panaxjaponicus
C.A.Meyer;Panax schinsen
gNees var.japonicumMakin
o;Panax pseudo−ginseng(Wi
ll.) subsp.japonicus Har
a)、サンシチニンジン(Panaxnotogins
eng(Burkill)F.H.Chen;Pana
x sanchi Hoo;Panaxpseudo−
ginseng Wallich var.notog
inseng(Burkill)Hoo et Tse
ng)、又はアメリカニンジン(Panax quin
quefolium L.)等を挙げることができる。
また、薬用人参から、ジンセノサイドRhおよび/ま
たはジンセノサイドRgが多く含有する細胞を選択し
て培養して大量に得ることも可能である。例えば、オタ
ネ人参の根か、成長点を培養し、そのなかで、収量の多
い細胞を選択すれば大量に得ることができる。また、特
開平8−208688号公報にあるようにテルペンから
も合成が可能である。本発明では、ジンセノサイドRh
および/またはジンセノサイドRgを多く含む植物
を酵素処理後抽出する事により大量のジンセノサイドR
および/またはジンセノサイドRgを得た。Rh
(1,400〜1,500mg)、Rh(280〜
300mg)含有の人参組成物を得るには以下の方法に
よる。定法の液体培地に小麦ふすま3%、人参粉末1%
を添加しAspergillus属の麹菌を接種したも
のを20〜30℃、60〜80時間好気的に培養する。
その後遠心分離にて菌体を除去し、培養液に50〜80
%のエタノール溶液を加えて酵素タンパクを沈殿、画取
する。次に得られた酵素タンパクを画取した量に応じて
0.02M酢酸ナトリウム(pH5.0)に再溶解し遠
心分離法にて不純物を除去した後、上澄液として酵素処
理溶液を得る。酵素処理溶液に粗サポニンを適当量加え
18〜24時間反応させ、その後エタノールにて不純物
を沈澱処理後、上澄液を減圧濃縮する。濃縮液を50〜
70%酢酸水溶液にて20倍に希釈しさらに4〜8時間
反応させた後、得られた反応液を凍結乾燥させ人参組成
物を得る。薬用人参(或いは組織培養物)からの抽出方
法は公知の方法を用いればよい。以下にその一例を挙げ
る。必要により有機溶媒例えば、ヘキサン、石油エーテ
ルを用いて脱脂したのち、水或いは低級脂肪族アルコー
ル(例えば、メタノール、エタノール)或いは水と低級
脂肪族アルコールを用いて抽出し、溶媒を除去したの
ち、n−ブタノールを加えて溶解し、これに水を加えて
よく攪拌し、n−ブタノール層を取り出したのち、蒸発
乾固する。残留物を低級脂肪族アルコールに溶かし、エ
ーテル中に攪拌注入し、得られた析出物をろ取する。こ
れをクロマトグラフィーを用いてジンセノサイドRh
とジンセノサイドRgを分取すればよい。さらには合
成することも可能であり一例を挙げれば、特開平3−2
08688号公報のような製造方法で得ることもでき
る。いずれも場合も純度には限定はなく、コストや用途
などによって精製度を調整して用いればよい。 【0006】ジンセノサイドRhおよび/またはジン
セノサイドRgを皮膚外用剤に配合するが、抽出方法
や配合目的などによって変化するが、配合量は固形分と
して0.0001〜10.0%が好ましい。また、他の
配合する原料は限定されることはないので、自由に選択
すればよいが、本発明の安全で有効性のある皮膚外用剤
という趣旨に反しない原料を選択することは当然のこと
である。このため、美白や抗酸化、細胞賦活(細胞老化
防止)、保湿、肌荒れ防止及びその改善等に効果のある
各種の薬剤と併用することは本発明の目的をさらに効果
的にする。また、用途等によって、クリーム、乳液、ロ
ーション、パック、スプレー、ジェル等任意の剤型より
選択することはなんら問題はない。 【0007】以下に実際の抽出方法の例である製造例と
製造例を配合した実施例を記載するが当然これらに限定
されることはない。 【0008】製造例−1 酵素処理後、120℃で2時間加熱処理した高麗人参を
200gをエタノール500mlで抽出してエタノール
抽出物を得、エタノールを蒸発させて除去した後、残り
の残渣を水200mlで懸濁させ、エーテル200ml
ずつ3回抽出した後、残りの水層を水で飽和されたブタ
ノールを200mlずつ3回抽出してサポニンが含有さ
れたブタノール抽出液を得た。このブタノール抽出液を
乾燥して酢酸エチル/メタノール/水(20:1:1)
の混合溶媒を溶出剤として用いてシリカゲルカラムクロ
マトグラフィーさせて目的とするジンセノサイドRg
を60%含有する分画2.7gを収得した。 【0009】製造例−2 製造例−1と同一の方法でジンセノサイドRhを0.
13g得た。 【0010】実施例は表1に示す処方で、A、Bともに
80℃で加温溶解し、BをAに撹拌しながら徐々に加え
乳化する。撹拌しながら冷却し35℃で撹拌を止め、放
置する方法でクリームを作成した。 【0011】 【表1】【0012】効果を確認するため、以下の実験を行っ
た。 試験1 皮膚免疫機能回復試験 8週齢のC3H/HeN雄マウスを4群に分け、第1群
〜第3群のマウスの剃毛した腹部に、10mJ/cm
/日の紫外線を4日間連続照射した。1日目、2日目、
3日目、4日目の照射直後に、第1群〜第2群のマウス
の照射部位にそれそれ製造例1〜2の2%液(溶媒は5
0%エタノール)を50μl/日塗布した。第3群のマ
ウスの照射部位には何も塗布しなかった。また第4群に
は紫外線を照射しなかった。照射終了1日後に、照射部
位(第4群のマウスにおいては、第1群〜第3群のマウ
スの照射部位と略同一の腹部)においてジニトロフルオ
ロベンゼン(DNFB)による接触アレルギー感作を行
った。さらに感作の5日後に両耳介にて惹起し、さらに
その1日後に両耳介の腫脹の値(惹起の1日後の耳介の
厚さから惹起前の耳介の厚さを引いた値)を測定し、接
触アレルギー反応の回復率(%)を次式により算出し
た。 【0013】回復率=(a−b)×100/(c−b) 【0014】ただし、aは第1群〜第2群の耳介腫脹の
値を、bは第3群の耳介腫脹の値を、cは第4群の耳介
腫脹の値を表す。結果を表2に示す。 【0015】 【表2】 【0016】試験2 人での有用性評価試験 21才から46才の女性ボランティア40名をランダム
に4群に分けた。右顔面に実施例、左顔面に比較例を1
日3回左右同量使用してもらった。(特に量の規定はし
なかった)3ヶ月後に肌の状態について以下の評価し
た。 自覚的評価 以下の基準で、肌の白さ、肌荒れ改善効果、肌のはり、
シワ改善効果、化粧ののりについて聞き取りした。結果
を表3に示す。(なお、試験期間中に皮膚の異常を訴え
た人はいなかった。また、表中の数字は平均値を表
す。) 使用前に比較して非常に改善した 3 使用前に比較して改善した 2 使用前に比較してややに改善した 1 使用前と変化なし 0 使用前に比較して悪化した −1 使用前に比較して悪化した −2 使用前に比較して非常に悪化した −3 【0017】 【表3】 【0018】試験3 安全性試験 以下の安全性試験を行った。 3−1 皮膚一次刺激性試験 背部を除毛した白色雄性家兎(一群3匹)の皮膚に適用
した。判定は、適用後24,48,72時間に一次刺激
性の評点法にて紅斑及び浮腫を指標として行った。検体
は製造例2と3の各0.5%水溶液を用いた。その結果
は、すべての動物において、紅斑及び浮腫を認めず陰性
と判定された。 【0019】3−2 皮膚累積刺激性試験 側腹部を除毛したハートレー系モルモット(雌性,一群
5匹)の皮膚に1日1回、週5回,0.5ml/匹を塗
布した。塗布は2週間行い、除毛は各週の最終塗布日に
行った。判定は、各塗布日及び最終塗布日の翌日に一次
刺激性の評点法にて紅斑及び浮腫を指標として行った。
検体は製造例2と3の各0.5%水溶液を用いた。その
結果は、すべての動物において、2週間に渡って何等、
紅斑及び浮腫を認めず陰性と判定された。 【0020】3−3 感作性試験 背部を除毛したハートレー系モルモット(雌性,一群5
匹)体重330〜400gのハートレー系の雌モルモッ
ト10匹の背部を剃毛し、製造例の0.5%水溶液20
μlを塗布してアジュバントパッチテストを行った。結
果は製造例2と3いずれも、すべての動物において、紅
斑及び浮腫を認めず陰性と判定された。 【0021】3−4 ヒトパッチテスト 23才から46才の女性ボランティア30名に、製造例
の0.5%水溶液20μl常法に従ってパッチテストを
行った。(貼付時間24時間)結果は製造例2と3いず
れも、30人とも貼付部位には何らの刺激性も認められ
ず、ヒトの皮膚に対する刺激性は陰性と判断された。 【0022】3−5 急性毒性試験 4時間絶食させたddy系マウス(雄性及び雌性,1群
5匹,5週齢)に製造例を200mg/kg量経口投与
し、毒性症状の発現、程度などを経時的に観察した。そ
の結果、製造例2と3何れも、すべてのマウスにおいて
14日間なんら異常を認めず、又、解剖の結果も異状が
なかった。 【0023】 【発明の効果】本発明上記の試験より皮膚免疫の機能を
回復し、正常化する機能を有し、実際にジンセノサイド
Rhおよび/またはジンセノサイドRgを用いた皮
膚外用剤は、肌荒れ改善効果、肌のはり、シワ改善効
果、化粧ののりが改善し、皮膚外用剤として有効性の高
いことがわかった。また、古くより食用とされており、
また各種の試験を行った結果からも安全性も全く問題な
いことは言うまでもない。
Description: BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an external preparation for skin which has a cell activating effect on pharmaceuticals, quasi-drugs and cosmetics, and particularly has a skin immunity regulating effect. More specifically, the present invention relates to a safe and effective external skin preparation containing an extract of ginsenoside Rh 2 and / or ginsenoside Rg 3 produced by an enzyme treatment method. [0002] Ginseng, rapeseed ginseng and the like (hereinafter abbreviated as ginseng) have been used as crude drugs since ancient times.
It is also compounded in skin external preparations such as cosmetics. (Japanese Patent Laid-Open No. 5
Nos. 0-95416, JP-A-55-127317, JP-A-58-113116 and JP-A-59-55809), and are widely used as hair restorers.
(Japanese Unexamined Patent Publication No. 60-38314, Japanese Unexamined Patent Publication No.
0, JP-A-60-222409, JP-A-60-255
No. 715) The use in cosmetics is mainly focused on activating cells. Recent studies have also shown that ginseng has immunomodulatory effects and is useful for cancer. Among them, ginsenoside Rh 2 and ginsenoside Rg 3, which are particularly contained in a large amount of wild ginseng, have been found to have a strong effect as one of recent research results. [0003] Skin external preparations such as cosmetics are often used continuously for a long period of time, and are applied to organs having a large area such as skin. In addition, there is a variety of effects required for skin external preparations, and effects such as prevention of skin aging and rough skin are required. In the case of people of color, such as Japanese, whitening of the skin leads to beauty, and whitening is a great effect required for skin external preparations. In addition, the skin's functions include keeping the body from losing water from the body so that it can live even in dry air, and of course there are external physical and protective functions. Are also playing an important role. The skin is composed of keratinocytes of the epidermis, Langerhans cells, dendritic cells of the dermis, vascular endothelial cells, macrophages, and the like.
It is believed that it is processed immediately upon contact, migrates to the lymph nodes and presents it to T cells, and a series of subsequent immune response reactions begins. It is also known that exposure to ultraviolet light and stress can reduce this immune function, and may cause various skin diseases (skin abnormalities including those that do not lead to disease) even without carcinogenesis. Normalization of skin immunity is an item that should be fully considered.
In addition, the function of immunity on the skin is very different from that of other organs, and the function on the skin is often different even if it is known to be related to other immunity. Means for Solving the Problems As a result of intensive studies in consideration of safety and effectiveness on the skin, ginsenoside Rh 2 and / or ginsenoside Rg 3 which are useful components contained in plants such as carrots are used. It was found that the external preparation for skin used was optimal for the purpose of the present invention. In the present invention, a skin external preparation that is effective for the skin, such as a skin immunity normalizing effect and a cell activating effect, is formulated by blending ginsenoside Rh 2 and / or ginsenoside Rg 3 produced using an enzyme treatment method. Was studied and developed. [0005] Ginsenoside Rh 2 and / or ginsenoside Rg 3 can be obtained from whole or a part of a plant containing ginsenosides as it is, or from a processed (for example, dried, cut, blanched, steam-heated or powdered) plant. It is possible to extract. But,
Naturally, ginseng has a high content in ginseng, so it is often extracted from it. For example, Panaxginseng CA Me, a member of the family Aramiidae, is exemplified.
yer; Panax sinseng Nee
s), Panax japonicus
C. A. Meyer; Panax schinsen
gNees var. japonicumMakin
o; Panax pseudo-ginseng (Wi
ll. ) Subsp. japonicus Har
a), Panax notogins
eng (Burkill) F.R. H. Chen; Pana
x sanchi Hoo; Panaxpseudo-
ginseng Wallich var. notog
inseng (Burkill) Hoo et Tse
ng) or American carrot (Panax quin)
quefolium L. ) And the like.
Also, the ginseng, it is also possible to select the cells which are ginsenoside Rh 2, and / or ginsenoside Rg 3 contains a number obtained in large quantities by culturing. For example, a large amount can be obtained by culturing the roots or growing points of ginseng and selecting high-yield cells. Further, as described in JP-A-8-208688, synthesis can also be performed from a terpene. In the present invention, ginsenoside Rh
A large amount of ginsenoside R can be obtained by extracting a plant containing a large amount of ginsenoside Rg 3 after enzymatic treatment.
It was obtained h 2 and / or ginsenoside Rg 3. Rh
2 (1,400 to 1,500 mg), Rh 3 (280 to
The following method is used to obtain a ginseng composition containing 300 mg). 3% wheat bran and 1% carrot powder in a conventional liquid medium
And inoculated with Aspergillus koji mold, and cultured aerobically at 20 to 30 ° C. for 60 to 80 hours.
Thereafter, the cells were removed by centrifugation, and 50-80
% Ethanol solution is added to precipitate and fractionate the enzyme protein. Next, the obtained enzyme protein is redissolved in 0.02 M sodium acetate (pH 5.0) in accordance with the fractionated amount, and impurities are removed by centrifugation. Then, an enzyme-treated solution is obtained as a supernatant. An appropriate amount of crude saponin is added to the enzyme-treated solution and reacted for 18 to 24 hours. After that, impurities are precipitated with ethanol, and the supernatant is concentrated under reduced pressure. 50 ~ concentrate
After diluting 20 times with a 70% acetic acid aqueous solution and reacting for 4 to 8 hours, the obtained reaction solution is freeze-dried to obtain a ginseng composition. A known method may be used as an extraction method from ginseng (or tissue culture). An example is given below. If necessary, after defatting using an organic solvent such as hexane or petroleum ether, extracting with water or a lower aliphatic alcohol (for example, methanol or ethanol) or using water and a lower aliphatic alcohol, and removing the solvent, n -Add butanol to dissolve, add water to the mixture, stir well, take out the n-butanol layer, and evaporate to dryness. The residue is dissolved in a lower aliphatic alcohol, poured into ether with stirring, and the resulting precipitate is collected by filtration. This was purified by chromatography using ginsenoside Rh 2
And ginsenoside Rg 3 may be fractionated. Furthermore, it is also possible to synthesize them.
It can also be obtained by a manufacturing method as disclosed in JP 08688. In any case, the purity is not limited, and the purity may be adjusted depending on the cost, application, and the like. [0006] Ginsenoside Rh 2 and / or ginsenoside Rg 3 are blended in the external preparation for skin, and vary depending on the extraction method and blending purpose, but the blending amount is preferably 0.0001 to 10.0% as a solid content. In addition, since the other ingredients to be blended are not limited, they may be freely selected, but it is a matter of course that ingredients that do not contradict the purpose of the safe and effective skin external preparation of the present invention are selected. It is. For this reason, the use of various agents effective for whitening, antioxidation, cell activation (prevention of cell aging), moisturization, prevention of rough skin and improvement thereof makes the object of the present invention more effective. In addition, there is no problem in selecting an arbitrary dosage form such as a cream, an emulsion, a lotion, a pack, a spray, and a gel depending on the use and the like. [0007] Production examples, which are examples of actual extraction methods, and examples in which the production examples are blended are described below, but are not limited thereto. Preparation Example 1 After the enzyme treatment, 200 g of ginseng which had been heat-treated at 120 ° C. for 2 hours was extracted with 500 ml of ethanol to obtain an ethanol extract, and the ethanol was removed by evaporation. Suspended in 200 ml, ether 200 ml
After extracting three times each, the remaining aqueous layer was extracted three times with 200 ml of butanol saturated with water to obtain a butanol extract containing saponin. The butanol extract is dried and ethyl acetate / methanol / water (20: 1: 1)
Ginsenoside Rg 3 by silica gel column chromatography using a mixed solvent of
2.7 g of a fraction containing 60% was obtained. Production Example 2 Ginsenoside Rh 2 was added to 0.1 g of ginsenoside Rh 2 in the same manner as in Production Example 1.
13 g were obtained. In the examples, the formulations shown in Table 1 were dissolved by heating both A and B at 80 ° C., and B was gradually added to A while stirring to emulsify. The mixture was cooled with stirring, the stirring was stopped at 35 ° C., and a cream was prepared by leaving the mixture. [Table 1] The following experiment was conducted to confirm the effect. Test 1 Skin Immune Function Recovery Test Eight-week-old C3H / HeN male mice were divided into four groups, and 10 mJ / cm 2 was applied to the shaved abdomen of the mice of the first to third groups.
/ Day of UV irradiation for 4 consecutive days. Day 1, Day 2,
Immediately after the irradiation on the third day and the fourth day, the 2% liquids of Preparation Examples 1 and 2 (the solvent was 5
0% ethanol) was applied at 50 μl / day. Nothing was applied to the irradiated site of the mice in the third group. The fourth group was not irradiated with ultraviolet rays. One day after the end of the irradiation, contact allergy sensitization with dinitrofluorobenzene (DNFB) was performed at the irradiation site (in the mice of the fourth group, the abdomen substantially the same as the irradiation sites of the mice of the first to third groups). . Further, 5 days after the sensitization, it was induced in both ears, and one day later, the swelling value of the both ears (the thickness of the pinna before the induction was subtracted from the thickness of the pinna one day after the induction) Was measured, and the recovery rate (%) of the contact allergic reaction was calculated by the following equation. Recovery rate = (ab) × 100 / (c−b) where a is the value of pinna swelling in the first and second groups, and b is pinna swelling in the third group. And c represents the value of pinna swelling in the fourth group. Table 2 shows the results. [Table 2] Test for Evaluating Usefulness by Two Tests Forty female volunteers aged 21 to 46 were randomly divided into four groups. One example on the right face and one comparative example on the left face
The same amount was used three times a day. After 3 months (the amount was not specified), the following evaluation was performed on the condition of the skin. Subjective evaluation Based on the following criteria, skin whiteness, skin roughness improvement effect, skin stick,
We heard about wrinkle improvement effect and makeup paste. Table 3 shows the results. (No skin complained of any abnormal skin during the test period. The numbers in the table represent the average values.) Very improved compared to before use 3 Improved compared to before use 2 Slightly improved compared to before use 1 No change compared to before use 0 Degraded compared to before use -1 Degraded compared to before use -2 Very deteriorated compared to before use -3 [ [Table 3] Test 3 Safety Test The following safety test was performed. 3-1 Primary skin irritation test The test was applied to the skin of white male rabbits (three in a group) whose back was shaved. Judgment was made 24, 48, and 72 hours after application by primary irritation scoring using erythema and edema as indices. Samples used were the 0.5% aqueous solutions of Production Examples 2 and 3. As a result, in all animals, erythema and edema were not recognized and the result was judged to be negative. 3-2 Cumulative Skin Irritation Test 0.5 ml / animal was applied once a day, 5 times a week to the skin of a Hartley guinea pig (female, 5 animals per group) whose hair was removed from the abdomen. Application was performed for 2 weeks, and hair removal was performed on the last application day of each week. Judgment was made on the day following each application day and the day after the last application day by using the primary irritancy scoring method with erythema and edema as indices.
Samples used were the 0.5% aqueous solutions of Production Examples 2 and 3. The results show that in all animals,
No erythema and edema were observed, and the result was negative. 3-3 Sensitization test Hartley-type guinea pig with hair removed from the back (female, 5 per group)
The back of 10 female Hartley guinea pigs weighing 330 to 400 g was shaved, and the 0.5% aqueous solution 20 of the production example was used.
μl was applied and an adjuvant patch test was performed. As a result, in all of Production Examples 2 and 3, no erythema and edema were observed in all animals, and the animals were determined to be negative. 3-4 Human Patch Test A patch test was performed on 30 female volunteers aged 23 to 46 years old according to the conventional method of 20 μl of a 0.5% aqueous solution of the production example. (Applying time: 24 hours) As a result, in all of Production Examples 2 and 3, no irritation was observed at the application site in 30 persons, and the irritation to human skin was judged to be negative. 3-5 Acute Toxicity Test A 200 mg / kg dose of a production example was orally administered to ddy mice (male and female, 5 mice / group, 5 weeks old) which had been fasted for 4 hours. Was observed over time. As a result, none of Production Examples 2 and 3 showed any abnormality in all the mice for 14 days, and there was no abnormality in the dissection results. According to the present invention, the skin external preparation using ginsenoside Rh 2 and / or ginsenoside Rg 3 has a function of restoring and normalizing the function of skin immunity from the test described above. The improvement effect, skin swelling, wrinkle amelioration effect, and cosmetic sizing were improved, and it was found that the skin external preparation was highly effective. In addition, it has been considered edible since ancient times,
Needless to say, there is no problem in safety from the results of various tests.

フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) C07J 9/00 C07J 9/00 (72)発明者 ジュング サング ソー ソウル市カンナム区マオグサムドング 776−12 ワイルビル5F Fターム(参考) 4C083 AA122 AC022 AC072 AC122 AC242 AC352 AC422 AC442 AC482 AD152 AD491 AD492 AD572 CC02 DD27 EE12 EE13 FF01 4C086 AA01 AA02 EA19 MA01 MA04 MA63 NA06 NA07 NA14 ZA89 4C091 AA01 BB01 CC01 DD01 EE06 FF02 FF06 GG01 HH01 JJ03 KK01 LL02 LL03 LL06 LL09 MM01 NN01 PA02 PA05 PB05 QQ01 Continuation of the front page (51) Int.Cl. 7 Identification code FI Theme coat II (reference) C07J 9/00 C07J 9/00 (72) Inventor Jung Sang Saw 776-12 Maogsamdong, Gangnam-ku, Seoul Seoul 776-12 Wylville 5F F-term (reference) ) 4C083 AA122 AC022 AC072 AC122 AC242 AC352 AC422 AC442 AC482 AD152 AD491 AD492 AD572 CC02 DD27 EE12 EE13 FF01 4C086 AA01 AA02 EA19 MA01 MA04 MA63 NA06 NA07 NA14 ZA89 4C091 AA01 BB01 CC01 DD01 EE06 FF01 FF06 FF01 LL01 PA05 PB05 QQ01

Claims (1)

【特許請求の範囲】 【請求項1】酵素処理法により生産されたジンセノサイ
ドRhおよび/またはジンセノサイドRgを配合す
ることを特徴とする皮膚外用剤
Claims: 1. An external preparation for skin, comprising ginsenoside Rh 2 and / or ginsenoside Rg 3 produced by an enzyme treatment method.
JP2001398249A 2001-11-22 2001-11-22 Skin care preparation Pending JP2003160497A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001398249A JP2003160497A (en) 2001-11-22 2001-11-22 Skin care preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001398249A JP2003160497A (en) 2001-11-22 2001-11-22 Skin care preparation

Publications (1)

Publication Number Publication Date
JP2003160497A true JP2003160497A (en) 2003-06-03

Family

ID=19189300

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001398249A Pending JP2003160497A (en) 2001-11-22 2001-11-22 Skin care preparation

Country Status (1)

Country Link
JP (1) JP2003160497A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060021506A (en) * 2004-09-03 2006-03-08 주식회사 코리아나화장품 Cosmetic composition for skin regeneration containing ginsenoside rg3 and its derivatives as active ingredient
JP2007524627A (en) * 2003-06-23 2007-08-30 ジェロン・コーポレーション Compositions and methods for increasing telomerase activity
US8481721B2 (en) 2009-05-18 2013-07-09 Telomerase Activation Sciences, Inc. Compositions and methods for increasing telomerase activity
JP2013529899A (en) * 2010-05-14 2013-07-25 株式会社ジーシーエイチアンドピー Process for producing novel processed carrots or processed carrot extracts with increased ginsenoside ingredients
JP2014015462A (en) * 2012-07-05 2014-01-30 Amorepacific Corp External skin care preparation composition containing ginsenoside f2 extracted from hydroponically-cultivated ginseng
WO2014181852A1 (en) * 2013-05-10 2014-11-13 花王株式会社 Bathing agent composition
US9248088B2 (en) 2003-06-25 2016-02-02 Telomerase Activation Sciences, Inc. Compositions and methods for skin conditioning
CN109022529A (en) * 2018-08-17 2018-12-18 吉林农业大学 A kind of preparation method of ginsenoside enzymatic hydrolysis product
US10709749B2 (en) 2013-08-30 2020-07-14 Green Cross Wellbeing Corporation Composition for preventing and treating cancer-related fatigue, containing processed ginseng powder or processed ginseng extract having increased ginsenoside constituent

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524627A (en) * 2003-06-23 2007-08-30 ジェロン・コーポレーション Compositions and methods for increasing telomerase activity
US8759304B2 (en) 2003-06-23 2014-06-24 Telomerase Activation Science, Inc. Compositions and methods for increasing telomerase activity
US9248088B2 (en) 2003-06-25 2016-02-02 Telomerase Activation Sciences, Inc. Compositions and methods for skin conditioning
KR20060021506A (en) * 2004-09-03 2006-03-08 주식회사 코리아나화장품 Cosmetic composition for skin regeneration containing ginsenoside rg3 and its derivatives as active ingredient
US8481721B2 (en) 2009-05-18 2013-07-09 Telomerase Activation Sciences, Inc. Compositions and methods for increasing telomerase activity
US9913851B2 (en) 2009-05-18 2018-03-13 Telomerase Activation Sciences, Inc. Compositions and methods for increasing telomerase activity
US9403866B2 (en) 2009-05-18 2016-08-02 Telomerase Activation Sciences, Inc. Compositions and methods for increasing telomerase activity
JP2013529899A (en) * 2010-05-14 2013-07-25 株式会社ジーシーエイチアンドピー Process for producing novel processed carrots or processed carrot extracts with increased ginsenoside ingredients
US9512453B2 (en) 2010-05-14 2016-12-06 Green Cross Wellbeing Corporation Method for preparing novel processed ginseng or an extract thereof, the usually minute ginsenoside content of which is increased
JP2014015462A (en) * 2012-07-05 2014-01-30 Amorepacific Corp External skin care preparation composition containing ginsenoside f2 extracted from hydroponically-cultivated ginseng
CN105188658A (en) * 2013-05-10 2015-12-23 花王株式会社 Bathing agent composition
JP2014237633A (en) * 2013-05-10 2014-12-18 花王株式会社 Bathing agent composition
WO2014181852A1 (en) * 2013-05-10 2014-11-13 花王株式会社 Bathing agent composition
TWI627972B (en) * 2013-05-10 2018-07-01 花王股份有限公司 Bath preparation composition
RU2667641C2 (en) * 2013-05-10 2018-09-21 Као Корпорейшн Detergent composition
US10709749B2 (en) 2013-08-30 2020-07-14 Green Cross Wellbeing Corporation Composition for preventing and treating cancer-related fatigue, containing processed ginseng powder or processed ginseng extract having increased ginsenoside constituent
US11464821B2 (en) 2013-08-30 2022-10-11 Green Cross Wellbeing Corporation Composition for reducing cancer cachexia or weight loss caused by anticancer drug therapy or radiation therapy comprising ginseng extract having increased ginsenoside Rg3 and Rh2
CN109022529A (en) * 2018-08-17 2018-12-18 吉林农业大学 A kind of preparation method of ginsenoside enzymatic hydrolysis product

Similar Documents

Publication Publication Date Title
JP3499616B2 (en) Application to hydroxytyrosol, melanin production inhibitor or lipid peroxide production inhibitor
JP2000128765A (en) Skin cosmetic
JP2003160497A (en) Skin care preparation
JPH115727A (en) Skin cosmetic
JPH1180002A (en) Preparation for external use for skin preventing aging
JP2001122733A (en) Catalase production-promoting preparation and skin preparation for external use containing the same
JPH10330281A (en) Activator for fibroblast and skin preparation for external use containing the same
JP3742767B2 (en) Hair conditioner consisting of extracts of Asagaokakaraksa and other herbal extracts
JP2001114636A (en) Hyaluronic acid production and catalase production promoting agent, fibroblast activating agent and skin lotion
KR100525722B1 (en) Topical constituents of ginsenoside Rh2 and ginsenoside Rg3
JP2001122763A (en) Composition for external use
JPH11158054A (en) Skin lotion
JPH07277920A (en) Cosmetic containing steam-distilled water and/or extract of lemongrass
JP2000212058A (en) Skin cosmetic, active oxygen eliminator, esterase inhibitor, and collagenase inhibitor
JP3105664B2 (en) External preparation for skin
JP3822959B2 (en) Anti-aging skin external preparation
JP2004307437A (en) Skin care preparation for external use for preventing aging
US20020041908A1 (en) Iridacea extracts for stimulating the immune system
JP2000109420A (en) Cosmetic against aging
JP2005145900A (en) Hair-growing agent composition and itching inhibitor
JP2002161043A (en) Skin care preparation
JPS61254510A (en) External agent for skin
JP2000143527A (en) Hyaluronic acid production promoter and skin preparation for external use containing the same
JPH08337534A (en) Suppressant for melanogenesis
JP2755783B2 (en) Cosmetics